Cortagen: A Cortex-Tropic Tetrapeptide Bioregulator

Research summary. Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro, AEDP) belonging to the Khavinson short-peptide bioregulator family. As its name suggests, the peptide has been studied primarily for effects on cortical neural tissue and the broader central nervous system, with reported activity in nerve regeneration, neuroinflammation, and oxidative-stress models in rodents.

Molecular profile

• Sequence: Ala-Glu-Asp-Pro (AEDP)
• Molecular formula: C₁₇H₂₇N₅O₈
• Molecular weight: ~430.4 g/mol
• PubChem CID: 18439621
• Class: Short peptide bioregulator (Khavinson peptides) — cortical/CNS tropism

Mechanism of action

Cortagen is described in the source literature within the bioregulator framework: a small unmodified tetrapeptide proposed to enter the nucleus and engage chromatin in a tissue-selective manner to modulate gene transcription. Reported molecular endpoints include:

• Chromatin decondensation. The Khavinson group has reported that Cortagen exposure decondenses heterochromatin in nerve-tissue cell preparations, reopening transcriptionally silenced regions of the genome.
• Transcriptome reprogramming. Microarray and RNA-sequencing analyses have reported expression changes affecting on the order of ~110 genes across ~234 DNA regions following Cortagen administration in rat models, with enrichment for ribosomal activity and stress-response gene sets.
• Antioxidant pathway support. Reductions in lipid peroxidation markers (MDA, conjugated dienes) and elevation of antioxidant enzyme activity in serum and brain tissue have been described.

Preclinical research highlights

Peripheral nerve regeneration. A frequently cited finding from the Cortagen literature involves rat sciatic-nerve transection models. Intramuscular administration of Cortagen (reported at 10 µg/kg in the source studies) was associated with a roughly 40% increase in regenerating nerve fibres and improved functional recovery scores compared with controls, suggesting a possible adjunctive role to surgical nerve repair in research models.

Cortical neuroinflammation. In rodent models of cerebral ischaemia and inflammation, Cortagen has been reported to reduce expression of pro-inflammatory cytokines, attenuate microglial activation markers, and preserve cortical neuron morphology in histological sections.

Oxidative-stress models. Rat studies have reported reductions in lipid peroxidation products (MDA) and elevations in antioxidant enzyme activity (SOD, catalase) in serum and brain tissue following Cortagen administration in models of oxidative challenge.

Immunomodulation. Cortagen has been reported to modulate IL-2 signalling and T-cell-related immune parameters, an effect described in the source literature within the context of autoimmune-relevant models. The extent and reproducibility of these findings is more limited than the nerve-regeneration data.

Limitations of the evidence base

Cortagen is subject to the methodological caveats common to the Khavinson bioregulator family:

• The supporting literature is concentrated in a single research programme.
• Independent confirmation of the proposed direct chromatin-engagement mechanism for unmodified tetrapeptides is limited.
• Functional outcome measures derive primarily from cell-culture and rodent endpoints rather than independently replicated translational studies.
• No registered Phase 2 or Phase 3 clinical trials of Cortagen appear in major Western trial registries.

That said, the nerve-regeneration findings are sufficiently striking that they have attracted some interest beyond the original research programme as a model for studying tetrapeptide effects on Schwann-cell biology and axonal regrowth.

Position within the bioregulator family

Cortagen is the cortex/nervous-system-tropic counterpart in the Khavinson family, alongside related CNS-active members such as Pinealon (which is studied in pineal/CNS contexts) and the longer-chain Cerebrolysin (a porcine-derived neuropeptide preparation). Among bioregulator-family peptides, Cortagen has one of the more concrete reported in-vivo functional readouts (nerve regeneration), which has supported its continued use as a research tool.

Current research status

Cortagen remains an investigational research peptide. It is not approved as a therapeutic by any major regulatory authority. Its principal roles in current research include:

• A reference compound in the Khavinson bioregulator family with CNS tropism
• A research tool in peripheral nerve regeneration and central neuroinflammation models
• A geroprotective candidate within the broader bioregulator research framework

Key takeaways for researchers

• Cortagen is a tetrapeptide (Ala-Glu-Asp-Pro) member of the Khavinson short-peptide bioregulator family, with reported CNS tropism.
• Reported effects include enhanced peripheral nerve fibre regeneration, attenuated cortical neuroinflammation, and antioxidant pathway support.
• The proposed mechanism involves chromatin decondensation and tissue-selective transcriptional modulation.
• The supporting literature originates predominantly from a single research programme.
• Cortagen is not an approved therapeutic.

References

1. Khavinson VK, Linkova NS, Tarnovskaya SI, et al. Short peptides stimulate cell regeneration: from theory to clinical practice. Bulletin of Experimental Biology and Medicine. 2014;156(3):283–289.
2. Khavinson VK, Anisimov VN. Peptide regulation of aging: 35-year research experience. Bulletin of Experimental Biology and Medicine. 2009;148(1):94–97.

---

This article is provided for educational and research purposes only. Cortagen is a research peptide. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.